Results 201 to 210 of about 224,987 (336)

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

open access: yesBMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou   +6 more
wiley   +1 more source

Abstract QS20: HIF-1α Deletion Modulates the Ratio of Treg/Th17 cells in CD4 T Cells and Improves Vascularized Composite Allotransplantation Survival under Costimulatory Blockade

open access: gold, 2019
Cheng‐Hung Lin   +6 more
openalex   +1 more source

Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sjögren’s syndrome [PDF]

open access: bronze, 2017
Fan Xiao   +12 more
openalex   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

open access: yesBarrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

Supplementary Figure Legends from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients

open access: gold, 2023
Sophie Viaud   +11 more
openalex   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy